Loading stock…

Stoke Therapeutics, Inc. (STOK) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Stoke Therapeutics, Inc.

STOKMarket cap $1.57BPrice $24.3

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops RNA-based medicines that restore protein levels by targeting the root cause of genetic diseases, rather than just masking symptoms. Its lead therapy tackles a severe childhood epilepsy with no disease-modifying treatment currently on the market.

In Bastion Portfolios?

52W Return-28%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+146%10

Revenue Forecast

Rev CAGR (1y)-84%1

Rev CAGR (3y)-12%1

Rev CAGR (5y)+25%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-810%1

Net Income Margin-754%1

Free Cash Flow Margin-655%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-61%1

ROA-53%1

Earnings Stabilityna–

GEAR+VERY WEAK2

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV4.54

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-11.5%1

Dividend Yieldna–

Momentum

Short term

1 month return-19%1

3 month return-26%1

YTD return-23%2

Mid term

Price vs 52wHigh60%2

1 year return-20%2

Long term

3 year return+524%10

5 year return+8%4

Risk Shield

Price Risk

Beta1.81

Volatility59%2

Free Cash Flow

Free Cash Flow Margin-655%1

Free Cash Flow Yield-11.5%1

Quality

ROCE-64%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

STOKStoke Therapeutics

Revenue FY25$184M

GROWTH RATING↗

WEAK32 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+146%10

Revenue, next 1Y-84%1

Revenue, next 3Y, CAGR-12%1

Revenue, next 5Y, CAGR+25%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 146%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

The runway holds up: revenue is set to grow 25%/yr over five years.10/10

WATCH

Revenue is set to shrink 12%/yr over the next 3 years, a little behind the market.4/10

WEAKNESSES

Growth is the weak spot here, trailing 68% of companies worldwide.

Revenue grew 146%/yr over the last 3 years, but it is set to shrink 12%/yr from here.

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Maturing Grower

Growth is a weak point here: a business heading into decline. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK14 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-19%1

3-month return-26%1

YTD return-23%2

MID & LONG-TERM▾SCORE

% of 52-week high60%2

1-year return-20%2

3-year return+524%10

5-year return+8%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +524% over three years and +7.9% over five, ahead of 60% of the market.

WATCH

None flagged.

WEAKNESSES

It's down 20% over the past year, now 40% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-19%), over three months (-26%) and so far this year (-23%).

BOTTOM LINE

Outperformer in a Drawdown

A proven multi-year compounder now in a meaningful pullback well below its 52-week high. This is the classic fork: either a buy-the-dip in an intact uptrend, or the early stage of a trend change. Wait for the short-term slide to stabilise before adding. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Stoke Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

STOKStoke Therapeutics

Revenue FY25$184M

GROWTH RATING↗

WEAK32 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+146%10

Revenue, next 1Y-84%1

Revenue, next 3Y, CAGR-12%1

Revenue, next 5Y, CAGR+25%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 146%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

The runway holds up: revenue is set to grow 25%/yr over five years.10/10

WATCH

Revenue is set to shrink 12%/yr over the next 3 years, a little behind the market.4/10

WEAKNESSES

Growth is the weak spot here, trailing 68% of companies worldwide.

Revenue grew 146%/yr over the last 3 years, but it is set to shrink 12%/yr from here.

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Maturing Grower

Growth is a weak point here: a business heading into decline. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK14 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-19%1

3-month return-26%1

YTD return-23%2

MID & LONG-TERM▾SCORE

% of 52-week high60%2

1-year return-20%2

3-year return+524%10

5-year return+8%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +524% over three years and +7.9% over five, ahead of 60% of the market.

WATCH

None flagged.

WEAKNESSES

It's down 20% over the past year, now 40% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-19%), over three months (-26%) and so far this year (-23%).

BOTTOM LINE

Outperformer in a Drawdown

04Value

Are you paying a fair price for it?

Stop guessing on Stoke Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community